Pharmaceutical registration intelligence

Every drug, in every market, in one search.

PharosPharma is fast and easy access to marketing authorizations, product registrations, manufacturing information, regulatory data, and portfolio insights from markets around the world. Monitor products, companies, active substances, and approval trends through a single searchable platform and advanced analytical tools.

  • ESWEGOVY 7,2 MG SOLUCION INYECTABLE EN PLUMA PRECARGADA
  • RUСемуглин слим
  • UAВЕГОВІ ФЛЕКСТАЧ
  • KZВегови®
  • FRWEGOVY 0,25 mg, FlexTouch solution injectable en stylo prérempli
  • CHRybelsus N 1.5 mg, Tabletten
  • INSemaglutide Injection
  • BRYLUMÉC
One schemaSemaglutideATC A10BJ06records869registries35
Semaglutide in eight registries — as published and as you search it.

Built for the teams who live in registries

1 / 5

For Regulatory Affairs

Stay Ahead of Global Registration Status

  • Monitor marketing authorizations, product registrations, and manufacturing information.
  • Track regulatory updates and approval histories across global markets.
  • Quickly identify regulatory pathways and support submission planning.

For Strategy

Turn Global Data Into Strategic Decisions

  • Analyze approval trends, competitive landscapes, market activity, and product portfolios across countries.
  • Identify growth opportunities by uncovering underserved markets, white spaces, emerging therapeutic areas, and regions with limited competitive presence.
  • Support long-term portfolio and market strategies with insights available at a glance.

For Portfolio Management

Build a Smarter Pipeline with Global Market Intelligence

  • Gain a comprehensive view of products, active substances, manufacturers, and regulatory positioning.
  • Identify portfolio gaps, evaluate lifecycle opportunities, and prioritize assets with greater confidence.
  • Uncover opportunities for new launches, geographic expansion, and portfolio optimization.

For Business Development

Discover New Licensing and Partnership Opportunities

  • Explore marketed products, manufacturers, rights holders, and dossier and approval status across global markets.
  • Identify potential partners, benchmark competitors, and uncover opportunities for in-licensing and out-licensing.
  • Accelerate opportunity assessment with insights into asset availability, market presence, and regulatory maturity across regions.

For Market Access

Understand Market Access Landscapes Across Countries

  • Optimize market entry and expansion strategies with data-driven insights for informed access decisions.
  • Evaluate competitive intensity, market maturity, and white-space opportunities across regions and therapeutic areas.
  • See how competitors position their products and understand the access landscape in each market.

All registries in one table

Semaglutide (ATC A10BJ06) as it appears in the registries: a sample of 8 rows out of 869.

CountryTrade name (as registered)Authorization holderFormStatusRegistered
ESSpainWEGOVY 7,2 MG SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/SInjectionActive2026-07-22
USUnited StatesWegovyNovo Nordisk Pharmaceutical Industries, LPTabletActive2026-01-06
CHSwitzerlandRybelsus N 1.5 mg, TablettenNovo Nordisk Pharma AGTabletActive2025-11-28
ZASouth AfricaSEMAGARDRanbaxy Pharmaceutical (Pty) Ltd—Active2026-06-30
RURussiaСемуглин слимАкционерное общество "Фармасинтез-Норд" (АО "Фармасинтез-Норд")Solution for injectionActive2026-08-06
AUAustraliaOZEMPIC semaglutide (rys) 2.68 mg/mL solution for injection pre-filled penNovo Nordisk Pharmaceuticals Pty LtdSolution for injectionActive2026-06-26
INIndiaSemaglutide InjectionNatco Pharma Limited—Active2026-08-18
BRBrazilYLUMÉCEMS S/A—Active2026-08-31

Sample from public registries as of September 2026. The full platform adds registration numbers, ATC codes, composition, manufacturers, and expiry dates.

One registration

Every field, as the platform shows it

One of the 869 semaglutide registrations — OZEMPIC in the Australian Register of Therapeutic Goods — exactly as a subscriber sees it: values as the registry publishes them, with dosage form, strength and composition normalized alongside.

  • As publishedTrade name, holder, dosage form and dates exactly as the registry records them — nothing rewritten.
  • Normalized alongsideDosage form mapped to EDQM standard terms and strength parsed into value and unit, so filters work the same in every registry.
  • Composition with rolesActive substances with their amounts and every excipient — wherever the registry publishes them.
  • One status vocabularyActive, suspended, cancelled or expired — one status vocabulary across 58 countries and ~25 languages.
  • Traceable to the sourceRegistry code, record number and last update on every card.

OZEMPIC semaglutide (rys) 2.68 mg/mL solution for injection pre-filled pen

semaglutide

ActiveTGA_AU

General information

Reg. number
388180
Reg. date
26.06.2026
Expiry date
—
Circulation period
Registered
MA Holder
Novo Nordisk Pharmaceuticals Pty Ltd
Country
Australia
Source
TGA_AU #388180
Last updated
10.09.2026 15:23

Dosage forms

Injection, solution

Solution for injectionParenteral

Dosage: 2.68 mg/ml

As registered: 2.68 mg/mL

Pack sizes

  • Cartridge, Glass Type I Clear; pack size: 1

Shelf life: 24 Months

Storage conditions: Store at 2 to 8 degrees Celsius; Do not Freeze; Refrigerate

Pharmaceutical substances

  • INN: semaglutide2.68 mg/ml

    Active
  • Substance: dibasic sodium phosphate dihydrate

    Excipient
  • Substance: propylene glycol

    Excipient
  • Substance: phenol

    Excipient
  • Substance: hydrochloric acid

    Excipient
  • Substance: sodium hydroxide

    Excipient
  • Substance: water for injections

    Excipient

For Enterprise

Leverage private connectivity and flexible integrations to deliver pharmaceutical intelligence directly into your CRM, analytics, regulatory, and internal business systems.

Explore more
  • APIquery from your systems
  • Bulk exportson a schedule
  • Webhookswhen records change

Unlock global pharmaceutical intelligence to make smarter, faster, and more data-driven decisions

Start a free trial — no card required. Full search, filters, and analytics throughout the trial.

Start free trial